Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0001628280-25-007715
Filing Date
2025-02-25
Accepted
2025-02-25 16:02:49
Documents
111
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K bcrx-20241231.htm   iXBRL 10-K 2177984
2 EX-10.50 bcrx-20241231xex10_50.htm EX-10.50 13660
3 EX-19 insidertradingpolicy.htm EX-19 63011
4 EX-21 bcrx-20241231xex21.htm EX-21 9803
5 EX-23 bcrxfy24formconsentxex23.htm EX-23 6706
6 EX-31.1 bcrx-20241231xex311.htm EX-31.1 9749
7 EX-31.2 bcrx-20241231xex312.htm EX-31.2 9746
8 EX-32.1 bcrx-20241231xex321.htm EX-32.1 6019
9 EX-32.2 bcrx-20241231xex322.htm EX-32.2 5515
15 bcrx-20241231_g1.jpg GRAPHIC 118381
  Complete submission text file 0001628280-25-007715.txt   11479410

Data Files

Seq Description Document Type Size
10 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT bcrx-20241231.xsd EX-101.SCH 78890
11 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT bcrx-20241231_cal.xml EX-101.CAL 101258
12 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT bcrx-20241231_def.xml EX-101.DEF 327812
13 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT bcrx-20241231_lab.xml EX-101.LAB 896407
14 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT bcrx-20241231_pre.xml EX-101.PRE 636016
114 EXTRACTED XBRL INSTANCE DOCUMENT bcrx-20241231_htm.xml XML 1653391
Mailing Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703
Business Address 4505 EMPEROR BOULEVARD SUITE 200 DURHAM NC 27703 919-859-1302
BIOCRYST PHARMACEUTICALS INC (Filer) CIK: 0000882796 (see all company filings)

EIN.: 621413174 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 000-23186 | Film No.: 25662920
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)